We are live on ! Find out more
OM icon

Outset Medical

149 hedge funds and large institutions have $721M invested in Outset Medical in 2022 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 58 increasing their positions, 34 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

344% more call options, than puts

Call options by funds: $9.57M | Put options by funds: $2.15M

71% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 34

0.45% less ownership

Funds ownership: 7.21%6.76% (-0.45%)

3% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 35

2% less funds holding

Funds holding: 152149 (-3)

69% less capital invested

Capital invested by funds: $2.33B → $721M (-$1.61B)

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
149
Holders Change
-3
Holders Change %
-1.97%
% of All Funds
2.51%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
34
Increased
58
Reduced
34
Closed
35
Calls
$9.57M
Puts
$2.15M
Net Calls
+$7.42M
Net Calls Change
+$159K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$107M +$1.65M +3,829 +0.8%
JP Morgan Chase
2
JP Morgan Chase
New York
$77.1M +$61.4M +142,680 +70%
Vanguard Group
3
Vanguard Group
Pennsylvania
$64.6M +$579K +1,347 +0.5%
BlackRock
4
BlackRock
New York
$48M -$25.3M -58,783 -21%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$42.3M +$12.4M +28,909 +18%
BG
6
Bellevue Group
Switzerland
$34.6M +$8.88M +20,638 +15%
CIP
7
Champlain Investment Partners
Vermont
$24.8M -$10.7M -24,971 -18%
Allspring Global Investments
8
Allspring Global Investments
North Carolina
$22.1M -$15.9M -36,906 -27%
State Street
9
State Street
Massachusetts
$17.3M +$2.89M +6,712 +9%
WA
10
Wasatch Advisors
Utah
$17M +$12.6M +29,389 +63%
EHI
11
Eagle Health Investments
Connecticut
$15.1M +$19.8M +45,998 +210%
PA
12
Perceptive Advisors
New York
$14.8M -$25.4M -58,978 -47%
Jennison Associates
13
Jennison Associates
New York
$14M -$14.1M -32,861 -34%
RI
14
RTW Investments
New York
$13.5M +$287K +666 +1%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$13M -$1.96M -4,566 -7%
Citadel Advisors
16
Citadel Advisors
Florida
$12M -$668K -1,553 -3%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$11.8M +$74K +172 +0.3%
CWG
18
C WorldWide Group
Denmark
$11.1M +$21.5M +50,000 New
Ensign Peak Advisors
19
Ensign Peak Advisors
Utah
$9.12M +$15M +34,849 +577%
Barclays
20
Barclays
United Kingdom
$8.94M +$17M +39,574 +7,610%
Fiera Capital (Canada)
21
Fiera Capital (Canada)
Quebec, Canada
$8.79M -$273K -635 -2%
Massachusetts Financial Services
22
Massachusetts Financial Services
Massachusetts
$7.03M -$102K -236 -0.7%
TCM
23
TimesSquare Capital Management
New York
$6.96M -$8.53M -19,834 -39%
PVI
24
Pura Vida Investments
New York
$6.59M -$895K -2,080 -7%
Northern Trust
25
Northern Trust
Illinois
$6.2M -$304K -707 -2%

OM Hedge Fund Activity: Q2 2022 in Review

149 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Outset Medical (OM) for Q2 2022, worth a combined $721M — down 69% from $2.33B a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of OM and 34 opened new positions — a net loss of 1 holder — while 34 trimmed existing stakes and 58 added.

The largest buyer was JP Morgan Chase, adding an estimated $61.4M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $128M sold.

  • 149 institutional investors held Outset Medical (OM) as of Q2 2022, down from 152 in Q1 2022.
  • Funds reported $721M of Outset Medical stock for Q2 2022, down 69% quarter-over-quarter.
  • 34 funds opened new Outset Medical positions in Q2 2022 and 35 closed out, a net change of -1 holder.
  • The largest Outset Medical buyer in Q2 2022 was JP Morgan Chase, an estimated $61.4M added.
  • The largest Outset Medical seller in Q2 2022 was PFM Health Sciences, an estimated $128M sold.

Based on aggregated 13F filings for Q2 2022.